| 产品名称 | Peptides EP08114_1 | PRAME 425-433 (HLA-A*02:01) |
|---|---|
| 目录号 | EP08114_1 |
| 别名 | PRAME 425-433 (HLA-A*02:01) |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP08114_1 | 1 mg | 咨询 | 咨询 |
Peptides EP08114_1 | PRAME 425-433 (HLA-A*02:01)
品名：PRAME 425-433 (HLA-A*02:01)
货号：EP08114_1
规格：1 mg
品牌：Peptides.de
产品描述
PRAME 425-433 (SLLQHLIGL) is a linear peptidic epitope (epitope ID 459114) studied as part of Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395), a cancer/testis antigen from Homo sapiens. PRAME is highly expressed in several solid tumors such as melanoma, epithelial ovarian cancer, multiple sarcoma subtypes and non-small cell lung cancer, while in healthy tissue it is almost exclusively restricted to the testicles. Therefore, it is a promising target for adoptive T cell therapies. PRAME 425-433 (SLLQHLIGL) was first described by Kessler et al. in 2001. In their experiments, cytotoxic T lymphocytes recognizing the high affinity binding, HLA-A*0201–restricted PRAME epitope specifically lysed melanoma, renal cell, lung, mammary, and cervical carcinoma cell lines.
| Protein | Melanoma antigen preferentially expressed in tumors |
| Species | Human |
| Application | Flow Cytometry |
| Indication | Cancer |
